Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 16Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Brain Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Gallbladder Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Solid Tumors 1Solid Tumor 1Sarcoma, Clear Cell 1Neoplasms, Unknown Primary 1Microsatellite Unstable Colorectal Cancer 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Histiocytosis, Sinus 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Histiocytic Disorders, Malignant 1Hematologic Neoplasms 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × cobimetinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡